Can Healthcare Stocks Continue their 2018 Rally?

Investors looking for defensive investments in an uncertain world may benefit from looking at healthcare stocks, which was the best-performing sector in 2018

David Brenchley 30 January, 2019 | 8:07AM
Facebook Twitter LinkedIn

Drugs, tablets, pharmaceuticals, healthcare, defensive investments

In an uncertain environment for both risk assets and economies, it may be prudent for investors to look towards more defensive investments.

Clearly, there are a number of non-equity-heavy asset classes that can do the job – infrastructure being one, gold another. But for those keen to stay risk-on and in equities, healthcare also has defensive qualities.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
Amgen Inc219.38 USD0.00Rating
Bristol-Myers Squibb Company61.31 USD0.00Rating
Carmignac Pf Patrimoine F GBP Acc138.10 GBP0.36Rating
Eli Lilly and Co230.10 USD0.00Rating
International Biotechnology Ord726.01 GBP-0.27Rating
Intuitive Surgical Inc1,037.27 USD0.00Rating
Polar Capital Healthcare Opports Inc46.79 USD0.04Rating
Quest Diagnostics Inc154.77 USD0.00Rating
Stryker Corp273.03 USD0.00Rating
Takeda Pharmaceutical Co Ltd3,813.00 JPY0.00Rating
TB Evenlode Global Income B GBP Acc153.24 GBP0.36Rating

About Author

David Brenchley

David Brenchley  is a Reporter for Morningstar.co.uk

© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement